Alternative investment giant Ares Management (ARES) is scheduled to release its fourth-quarter financial results before Thursday's market open, with analysts anticipating strong year-over-year revenue growth despite recent sector headwinds.
Infrastructure specialist Construction Partners (NASDAQ: ROAD) is poised to release its fourth-quarter results Thursday morning. With mixed performance last quarter and shifting analyst expectations, here’s a breakdown of what investors should watch.
AGCO is set to report its fourth-quarter earnings before the bell on Thursday, with analysts forecasting a year-over-year revenue decline. Investors will be watching closely for signs of resilience in the agricultural equipment sector.
As Haemonetics prepares to report its fiscal fourth-quarter results, investors are watching for signs of stabilization after a period of declining revenues and a significant stock price drop. The report will shed light on the company's performance amid a mixed landscape for medical equipment peers.
The iconic fashion house Ralph Lauren (NYSE:RL) is scheduled to release its fourth-quarter financial results before Thursday's market open. Analysts project a slowdown in revenue growth compared to last year's strong performance, setting the stage for a closely watched report.
As QuinStreet prepares to report its fiscal fourth-quarter results, investors are watching for signs of stability after a period of significant stock price pressure. Analysts anticipate a year-over-year revenue dip, setting the stage for a critical update on the company's trajectory.
All eyes are on Ladder Capital (LADR) as it prepares to release its quarterly results amid a challenging commercial real estate landscape and a track record of recent misses.
Former Brevard County elementary school principal Elizabeth Hill-Brodigan received probation after pleading no contest to charges related to a massive underage drinking party at her home, a case that has sparked debate over accountability for educators.
Minnesota's top corrections official voices frustration over vague federal plans to scale back a controversial immigration operation, citing eroded trust and demanding transparency in the investigation of two agent-involved shootings.
Amid a sharp sell-off in growth-oriented sectors, risk-averse capital flowed into stable, income-generating giants on Tuesday, highlighting a broader market rotation.
Netflix's proposed acquisition of Warner Bros. Discovery, valued at $82.7 billion, is undergoing intense antitrust scrutiny. U.S. regulators and lawmakers are examining the deal's potential impact on streaming competition, content diversity, and the future of live sports broadcasting, including the Olympics.
A disastrous software implementation sent Clorox's stock tumbling, but analysts argue the century-old consumer staples giant's dominant market positions and recovering operations signal a compelling rebound story.
Amid market volatility, a bullish case emerges for Procter & Gamble (PG), highlighting its resilient brand portfolio, consistent capital returns, and potential strategic shifts under new leadership.
Despite posting explosive revenue and earnings growth, UP Fintech Holding Limited trades at a significant discount. Analysts point to its successful pivot to Singapore and Hong Kong, robust balance sheet, and a potential 87% upside as catalysts for a major re-rating.
As Honeywell International advances its plan to separate its Aerospace unit, analysts see a classic value-unlocking story. Beyond the spin-offs, the conglomerate's significant stake in quantum computing firm Quantinuum adds a layer of high-tech optionality to its steady industrial core.
Senate Minority Leader Mitch McConnell was admitted to a hospital Monday evening for observation after reporting flu-like symptoms. His office states his condition is stable and a return to Capitol Hill is anticipated.
TransMedics Group, Inc. (TMDX), a pioneer in portable organ perfusion technology, is drawing significant investor interest. With its shift to a recurring revenue model and FDA approvals expanding its market, the company presents a compelling growth story in the medtech sector, despite a premium valuation.
Penumbra, Inc. (NYSE: PEN), a dominant force in thrombectomy devices, has seen its stock retreat amid a broad market shift away from healthcare. With fundamentals intact and a debt-free balance sheet, analysts see the dip as a buying opportunity ahead of key catalysts.
Despite commanding half the U.S. secondary ticket market and a strategic push into primary sales, StubHub Holdings (STUB) trades well below its IPO price. Analysts see a compelling value case as the company leverages its dominant position for growth.
The Clorox Company reported fiscal second-quarter results largely in line with internal forecasts, citing a challenging macro environment and temporary disruptions from its ongoing ERP system implementation. Management highlighted sequential improvement through the quarter and outlined a path to margin recovery and growth driven by innovation in the latter half of the fiscal year.
